| Literature DB >> 30717439 |
Francisco Cen-Pacheco1, Gerardo Valerio-Alfaro2, Dalia Santos-Luna3,4, José Javier Fernández5.
Abstract
A new cytotoxic cyclononapeptide, sclerin, cyclo(⁻Dab¹⁻Ser²⁻Tyr³⁻Gly⁴⁻Thr⁵⁻Val⁶⁻Ala⁷⁻ Ile⁸⁻Pro⁸⁻) (1), was isolated from the methanol extract of the seeds of Annona scleroderma, together with the known metabolite, cyclosenegalin A, cyclo(⁻Pro¹⁻Gly²⁻Leu³⁻Ser⁴⁻Ala⁵⁻Val⁶⁻Thr⁷⁻) (2). The planar structures for the two compounds were established by comprehensive analysis of NMR and ESI-HRMS data, and the absolute stereochemistry was stablished by Marfey's method. Compound 1 showed moderate cytotoxic activity against the human prostate carcinoma cell line DU-145 at µM concentration.Entities:
Keywords: Annona; cyclononapeptide; cyclopeptide; cytotoxic compound
Mesh:
Substances:
Year: 2019 PMID: 30717439 PMCID: PMC6384883 DOI: 10.3390/molecules24030554
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structure of the cyclopeptides isolated from the methanol extract of Annona scleroderma.
NMR data (CD3OD) for cyclononapeptide sclerin (1).
| Amino acid | Position | Sclerin (1) | |||
|---|---|---|---|---|---|
| δC | δH, mult. ( | 1H-1H COSY | HMBC | ||
|
| CO | 172.8 | |||
| αCH | 54.5 | 4.26, dd (3.1, 10.1) | β | Dab CO, Pro CO | |
| βCH2 | 21.9 | 1.95, m | α, γ | ||
| γCH2 | 49.6 | 2.70, m | β | ||
|
| CO | 171.0 | |||
| αCH | 71.5 | 3.61, m | β | Dab CO, Ser CO | |
| βCH2 | 60.4 | 3.70, m | α | ||
|
| CO | 173.6 | |||
| αCH | 52.3 | 5.08, m | β | Ser CO, Tyr CO | |
| βCH2 | 35.1, | 2.78, m | α | Tyr δCH, Tyr θCH | |
| γC | 127.9 | ||||
| δCH/θCH | 129.3 | 7.08, d (7.7) | ε/η | Tyr γC, Tyr ζC | |
| εCH/ηCH | 115.6 | 6.79, d (7.7) | δ/θ | Tyr γC, Tyr ζC | |
| ζC | 155.2 | ||||
|
| CO | 171.6 | |||
| αCH2 | 43.2, | 3.84, d (17.3) | Tyr CO, Gly CO | ||
|
| CO | 172.0 | |||
| αCH | 55.8 | 4.82, d (2.3) | β | Gly CO, Thr CO | |
| βCH | 68.9 | 4.53, dq (2.3, 6.2) | α, γ | ||
| γCH3 | 18.8 | 1.12, d (6.2) | β | Thr CO | |
|
| CO | 175.1 | |||
| αCH | 62.9 | 3.61, m | β | Thr CO, Val CO | |
| βCH | 28.8 | 1.95, m | α, γ, γ’ | ||
| γCH3 | 19.4 | 1.02, d (6.5) | β | ||
| γ′CH3 | 18.1 | 0.91, d (6.8) | β | ||
|
| CO | 175.6 | |||
| αCH | 51.3 | 4.13, q (7.4) | β | Val CO, Ala CO | |
| βCH3 | 16.5 | 1.39, d (7.4) | α | Ala CO | |
|
| CO | 170.8 | |||
| αCH | 55.4 | 4.28, m | β | Ala CO, Ile CO | |
| βCH | 35.5 | 1.99, m | α, γ, ε | ||
| γCH2 | 23.4 | 0.94, m | β, δ | ||
| δCH3 | 10.5 | 0.86, t (7.3) | γ | ||
| εCH3 | 16.8 | 0.65, d (6.4) | β | ||
|
| CO | 177.7 | |||
| αCH | 63.1 | 4.48, t (8.8) | β | Ile CO, Pro CO | |
| βCH2 | 29.0 | 1.91, m | α, γ | ||
| γCH2 | 24.6 | 1.97, m | β, δ | ||
| δCH2 | 47.4 | 3.43, m | γ | Pro CHα | |
Figure 2Key COSY and HMBC correlations observed for the cyclononapeptide sclerin (1).
In vitro growth inhibitory activity for compounds sclerin (1) and cyclosenegalin A (2) against human prostate carcinoma cell line DU-145.
| Compound | IC50 (μM) |
|---|---|
| Sclerin ( | 27.3 ± 4.19 |
| Cyclosenegalin A ( | 54.9 ± 2.35 |
| Doxorubicin | 1.1 ± 0.71 |